Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

The impact of perampanel and targeting AMPA transmission on anti-seizure drug discovery.

Lattanzi S, Striano P.

Expert Opin Drug Discov. 2019 Mar;14(3):195-197. doi: 10.1080/17460441.2019.1566318. Epub 2019 Jan 11. No abstract available.

PMID:
30633590
2.

The discovery and development of perampanel for the treatment of epilepsy.

Hanada T.

Expert Opin Drug Discov. 2014 Apr;9(4):449-58. doi: 10.1517/17460441.2014.891580. Epub 2014 Feb 24. Review.

PMID:
24559052
3.

Evaluation of perampanel as monotherapy for focal seizures: Experience from open-label extension studies.

Kwan P, Mintzer S, Laurenza A, Patten A, Cartwright K.

Epilepsy Behav Case Rep. 2017 Dec 1;9:1-5. doi: 10.1016/j.ebcr.2017.11.001. eCollection 2018.

4.

A novel anti-epileptic agent, perampanel, selectively inhibits AMPA receptor-mediated synaptic transmission in the hippocampus.

Ceolin L, Bortolotto ZA, Bannister N, Collingridge GL, Lodge D, Volianskis A.

Neurochem Int. 2012 Sep;61(4):517-22. doi: 10.1016/j.neuint.2012.02.035. Epub 2012 Mar 10.

PMID:
22433907
5.

Perampanel, a novel, non-competitive, selective AMPA receptor antagonist as adjunctive therapy for treatment-resistant partial-onset seizures.

Rektor I.

Expert Opin Pharmacother. 2013 Feb;14(2):225-35. doi: 10.1517/14656566.2013.754883. Epub 2012 Dec 23. Review.

PMID:
23259931
6.

Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist.

Rogawski MA, Hanada T.

Acta Neurol Scand Suppl. 2013;(197):19-24. doi: 10.1111/ane.12100. Review.

7.

Effect of perampanel, a novel AMPA antagonist, on benzodiazepine-resistant status epilepticus in a lithium-pilocarpine rat model.

Hanada T, Ido K, Kosasa T.

Pharmacol Res Perspect. 2014 Oct;2(5):e00063. doi: 10.1002/prp2.63. Epub 2014 Jul 15.

8.

Perampanel, an AMPA receptor antagonist: From clinical research to practice in clinical settings.

Tsai JJ, Wu T, Leung H, Desudchit T, Tiamkao S, Lim KS, Dash A.

Acta Neurol Scand. 2018 Apr;137(4):378-391. doi: 10.1111/ane.12879. Epub 2017 Dec 7. Review.

PMID:
29214650
9.

Perampanel, an antagonist of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors, for the treatment of epilepsy: studies in human epileptic brain and nonepileptic brain and in rodent models.

Zwart R, Sher E, Ping X, Jin X, Sims JR Jr, Chappell AS, Gleason SD, Hahn PJ, Gardinier K, Gernert DL, Hobbs J, Smith JL, Valli SN, Witkin JM.

J Pharmacol Exp Ther. 2014 Oct;351(1):124-33. doi: 10.1124/jpet.114.212779. Epub 2014 Jul 15.

PMID:
25027316
10.

The AMPA receptor antagonist NBQX exerts anti-seizure but not antiepileptogenic effects in the intrahippocampal kainate mouse model of mesial temporal lobe epilepsy.

Twele F, Bankstahl M, Klein S, Römermann K, Löscher W.

Neuropharmacology. 2015 Aug;95:234-42. doi: 10.1016/j.neuropharm.2015.03.014. Epub 2015 Mar 31.

PMID:
25839899
11.

Perampanel as monotherapy and adjunctive therapy for focal onset seizures, focal to bilateral tonic-clonic seizures and as adjunctive therapy of generalized onset tonic-clonic seizures.

Tyrlikova I, Brazdil M, Rektor I, Tyrlik M.

Expert Rev Neurother. 2018 Dec 18:1-12. doi: 10.1080/14737175.2019.1555474. [Epub ahead of print]

PMID:
30560703
12.

Discovery of 2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl)benzonitrile (perampanel): a novel, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropanoic acid (AMPA) receptor antagonist.

Hibi S, Ueno K, Nagato S, Kawano K, Ito K, Norimine Y, Takenaka O, Hanada T, Yonaga M.

J Med Chem. 2012 Dec 13;55(23):10584-600. doi: 10.1021/jm301268u. Epub 2012 Dec 4.

PMID:
23181587
13.

Perampanel: What is its Place in the Management of Partial Onset Epilepsy?

Ledingham DR, Patsalos PN.

Neurol Ther. 2013 Aug 30;2(1-2):13-24. doi: 10.1007/s40120-013-0012-3. eCollection 2013 Dec. Review.

14.

Long-term tolerability, safety and efficacy of adjunctive perampanel in the open-label, dose-ascending Study 231 and extension Study 233 in Japanese patients with epilepsy.

Usui N, Akamatsu N, Nakasato N, Ohnishi A, Kaneko S, Hiramatsu H, Saeki K, Miyagishi H, Inoue Y.

Seizure. 2018 Nov;62:26-32. doi: 10.1016/j.seizure.2018.09.012. Epub 2018 Sep 16.

15.

Perampanel in patients with refractory and super-refractory status epilepticus in a neurological intensive care unit.

Rohracher A, Höfler J, Kalss G, Leitinger M, Kuchukhidze G, Deak I, Dobesberger J, Novak H, Pilz G, Zerbs A, Trinka E.

Epilepsy Behav. 2015 Aug;49:354-8. doi: 10.1016/j.yebeh.2015.04.005. Epub 2015 May 9.

16.

The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist.

Patsalos PN.

Epilepsia. 2015 Jan;56(1):12-27. doi: 10.1111/epi.12865. Epub 2014 Dec 13. Review.

17.

Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies.

Steinhoff BJ, Ben-Menachem E, Ryvlin P, Shorvon S, Kramer L, Satlin A, Squillacote D, Yang H, Zhu J, Laurenza A.

Epilepsia. 2013 Aug;54(8):1481-9. doi: 10.1111/epi.12212. Epub 2013 May 10.

18.

Safety and efficacy of perampanel in children and adults with various epilepsy syndromes: A single-center postmarketing study.

Singh K, Shah YD, Luciano D, Friedman D, Devinsky O, Kothare SV.

Epilepsy Behav. 2016 Aug;61:41-45. doi: 10.1016/j.yebeh.2016.05.007. Epub 2016 Jun 11.

PMID:
27300147
19.

Pharmacokinetics, exposure-cognition, and exposure-efficacy relationships of perampanel in adolescents with inadequately controlled partial-onset seizures.

Villanueva V, Majid O, Nabangchang C, Yang H, Laurenza A, Ferry J, Hussein Z.

Epilepsy Res. 2016 Nov;127:126-134. doi: 10.1016/j.eplepsyres.2016.08.025. Epub 2016 Aug 22.

PMID:
27595590
20.

Seizure response to perampanel in drug-resistant epilepsy with gliomas: early observations.

Vecht C, Duran-Peña A, Houillier C, Durand T, Capelle L, Huberfeld G.

J Neurooncol. 2017 Jul;133(3):603-607. doi: 10.1007/s11060-017-2473-1. Epub 2017 May 10.

PMID:
28492978

Supplemental Content

Support Center